TesoRx Pharma, LLC., is breaking the "delivery deadlock" with a patented NeoliposomalTM platform that transforms existing pharmaceutical active ingredients into highly stable, versatile powders - taking existing, proven APIs and completely reimagining how they interact with the human body. The Neoliposomal technology can design custom delivery options that were previously impossible. This platform is versatile: Applications for parenteral use, such as our LiPax oncology platform, or oral delivery, led by our healthy aging therapy with oral testosterone treatment. TesoRx is not just making better drugs; we are making drugs work better and much safer.

Our platform is built on innovation, market scale, and clinical validation - A powder dosage form that achieves spontaneous dispersion in water, a groundbreaking technology with a  high drug loading capacity allowing for targeted therapy in challenging areas like the intracavitary spaces with no systemic exposure or higher bioavailability for our once daily dosing of oral testosterone. The massive market opportunity is unprecedented - we are targeting over 10 million patients in Testosterone Replacement Therapy (TRT) and for the LiPax platform, nearly 840,000 patients across Malignant Pleural Effusions (MPE) and Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trial studies in NMIBC have already demonstrated a 2-year Disease-Free Survival (DFS) rate of 83%, nearly double the current standard of care. With broad IP coverage reaching beyond 2037, we have a clear, protected path to market dominance."

ORAL DELIVERY of testosterone

Historically, oral testosterone has been limited by gastric degradation and hepatic 1st pass metabolism. The high first pass metabolism degrades the molecule in the liver, limiting its bioavailability. Testosterone is also poorly water soluble and has proven to be extremely difficult to administer orally in a safe and efficacious manner.

Utilizing TesoRx's novel drug delivery technology, Testosterone Undecanoate (TU) is formulated its a capsule that bypasses the stomach (gastric) entirely. Upon release of contents in the small intestine, neoliposomal TU complexes form spontaneously and are absorbed directly into the lymphatic system. From the lymph, TU is directly released into the blood stream, bypassing the liver, resulting in enhanced bioavailability of the drug. The slower conversion of Tu in the bloodstream enhances the overall therapeutic efficacy and enables once daily dosing.

Read more about TesoRx’s oral Testosterone products for Hypogonadism in men.

BREAKTHROUGH NEOLIPOSOME TECHNOLOGY TO TREAT LOCALIZED CANCER TUMORS

LiPax is the very first precision targeted, locally delivered taxane technology platform. Its growing pipeline targets areas of great unmet need in Bladder Cancer, Malignant Pleural Effusion (MPE), Upper Tract Urothelial Carcinoma, Stage II/III Ovarian Cancer, and Intraperitoneal Carcinoma.